

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

```

NEWS 1      Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display
           fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German
           patents
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese
           patents
NEWS 19 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Caplus enhanced with utility model patents from China
NEWS 27 JUL 16 Caplus enhanced with French and German abstracts
NEWS 28 JUL 18 CA/Caplus patent coverage enhanced
NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
                      CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
                      AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability
NEWS LOGIN      Welcome Banner and News Items
NEWS IPC8        For general information regarding STN implementation of IPC 8

```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

DICTIONARY FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10533931.str

10/ 533,931



```
chain nodes :
11 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20
chain bonds :
7-11 11-12 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 16-18 17-20 18-19 19-20
exact/norm bonds :
7-11 11-12 16-18 17-20 18-19 19-20 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
```

G1:C,O,S,N,SO2, [\*1]

Hydrogen count :

9:= exact 1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d L1

10/ 533,931

L1 HAS NO ANSWERS  
L1 STR



G1 C,O,S,N,SO2,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:26:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2 TO 124  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 17:27:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 60 TO ITERATE

100.0% PROCESSED 60 ITERATIONS 60 ANSWERS  
SEARCH TIME: 00.00.01

L3 60 SEA SSS FUL L1

=> file zcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 26 Jul 2007 VOL 147 ISS 5

FILE LAST UPDATED: 25 Jul 2007 (20070725/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s l3

L4 4 L3

=&gt; d his

(FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007)

FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 60 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007

L4 4 S L3

=&gt; d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:995977 ZCAPLUS

DOCUMENT NUMBER: 141:420417

TITLE: Therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis  
 Curwen, Jon Owen; Wedge, Stephen Robert  
 INVENTOR(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 PATENT ASSIGNEE(S): PCT Int. Appl., 111 pp.  
 SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098604	A1	20041118	WO 2004-GB1939	20040504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				



LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2004237132	A1	20041118	AU 2004-237132	20040504
CA 2519930	A1	20041118	CA 2004-2519930	20040504
EP 1620104	A1	20060201	EP 2004-731049	20040504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009742	A	20060509	BR 2004-9742	20040504
CN 1784232	A	20060607	CN 2004-80012089	20040504
JP 2006525304	T	20061109	JP 2006-506222	20040504
NO 2005004411	A	20051130	NO 2005-4411	20050923
US 2006223815	A1	20061005	US 2005-555389	20051103
MX 2005PA11858	A	20060217	MX 2005-PA11858	20051104

PRIORITY APPLN. INFO.:

GB 2003-10401	A	20030507
WO 2004-GB1939	W	20040504

GI



AB The invention relates to the use of an anti-angiogenic agent, such as I (preparation given), in combination with an inhibitor of the Src family of non-receptor tyrosine kinases, such as the II (preps. according to a previous patent given), in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis. The invention

provides for the Src kinase inhibitor to be administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent. Thus, 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline was coupled with 1-acetylpiperazine using KI in DMA to give I. The diastolic blood pressure profile of rats over a 24 h period after administration of a combination of 1.5 mg/kg of I and 25 mg/kg of II demonstrated that the contrasting blood pressure effects of the antiangiogenic agent and the Src kinase inhibitor were substantially counterbalanced.


IT 692054-06-1, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy)pyridin-4-yl]amino]-5-isopropoxyquinazoline  
692054-28-7, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy)pyridin-4-yl]amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline  
692054-33-4 692054-44-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Src kinase inhibitor; therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis)


RN 692054-06-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[[3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 692054-44-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-((3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857372 ZCAPLUS

DOCUMENT NUMBER: 141:350196

TITLE: Preparation of quinazoline derivatives as selective

Src kinase inhibitors

Curwen, Jon Owen

Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087120	A2	20041014	WO 2004-GB1286	20040323



WO 2004087120

A3

20050127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

## PRIORITY APPLN. INFO.:

GB 2003-7333

A 20030329


- AB The invention relates to the use of quinazoline derivative as a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke. For example, 7-[2-(4-acetyl piperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxy pyrid-4-ylamino)-5-isopropoxyquinazoline administered to rats at 25 mg/kg p.o. on day 1 showed hypotensive effect of 25 mmHg on day 2.
- IT 692053-03-5P, 4-(5-Chloro-2,3-methylenedioxy pyridin-4-ylamino)-7-(3-chloropropoxy)-6-methoxyquinazoline  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)
- RN 692053-03-5 ZCAPLUS
- CN 4-Quinoxalinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)



- IT 692054-44-7, 4-(5-Chloro-2,3-methylenedioxy pyrid-4-ylamino)-7-[2-[(3RS,4SR)-3,4-methylenedioxy pyrrolidin-1-yl]ethoxy]-5-isopropoxyquinazoline  
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)
- RN 692054-44-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-((3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 692053-13-7P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline  
 692054-06-1P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxy-pyridin-4-ylamino)-5-isopropoxyquinazoline  
 692054-11-8P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-6-methoxy-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]quinazoline  
 692054-16-3P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-6-Methoxy-7-[3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)propoxy]quinazoline  
 692054-22-1P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-6-methoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline  
 692054-28-7P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-5-(tetrahydropyran-4-yloxy)quinazoline  
 692054-33-4P, 4-(5-Chloro-2,3-methylenedioxy-pyridin-4-ylamino)-5-(tetrahydropyran-4-yloxy)-7-[2-[(3RS,4SR)-3,4-methylenedioxy-pyrrolidin-1-yl]ethoxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)


RN 692053-13-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-(4-(2-propynyl)-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692054-06-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692054-11-8 ZCAPLUS

CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 692054-16-3 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 692054-22-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692053-08-0P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-6-methoxyquinazoline 692053-18-2P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline 692053-23-9P,


7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxy-pyridin-4-ylamino)-5-isopropoxyquinazoline

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(reactant; preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)


RN 692053-08-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-18-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-23-9 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:430753 ZCAPLUS

DOCUMENT NUMBER: 141:1220

TITLE: Preparation of quinazolines as Src family non-receptor tyrosine kinase inhibitors for use in combination therapy with gemcitabine for treatment and prophylaxis of pancreatic cancer

INVENTOR(S): Barge, Alan

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043472	A1	20040527	WO 2003-GB4787	20031107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504666	A1	20040527	CA 2003-2504666	20031107
AU 2003279456	A1	20040603	AU 2003-279456	20031107
AU 2003279456	B2	20070517		
EP 1562612	A1	20050817	EP 2003-772404	20031107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016170	A	20050927	BR 2003-16170	20031107
CN 1711094	A	20051221	CN 2003-80103138	20031107
JP 2006508953	T	20060316	JP 2004-550784	20031107
NO 2005002312	A	20050606	NO 2005-2312	20050511
US 2006142297	A1	20060629	US 2005-534721	20051020
PRIORITY APPLN. INFO.:			GB 2002-26434	A 20021113
			WO 2003-GB4787	W 20031107

GI



AB The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent, gemcitabine, a pharmaceutical composition comprising such a combination, and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer. Examples include preps. for anilino- and (pyridylamino)quinazoline Src inhibitors (no Markush structure given) and bioassays demonstrating the synergistic effect of treating pancreatic cancer with a quinazoline Src inhibitor in combination with gemcitabine. For instance, 4-amino-5-chloro-2,3-methylenedioxy pyridine was coupled with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation of reactants given) in the presence of sodium hexamethyldisilazane in THF to afford the (pyridylamino)quinazoline I. Nude mice were injected with pancreatic tumor cells derived from the COLO 357 human pancreatic cancer cell line and treated with gemcitabine, the Src inhibitor, 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or a combination of the two. Evaluation for tumor growth and incidence of liver metastases showed that, compared with the weight of control tumors, tumor growth in animals treated with the combination was much reduced (1359 mg and 124 mg, resp.) to a level well below that achievable on the dosing of either gemcitabine or the Src inhibitor alone. In addition, there was no liver metastasis in the animals treated with the combination, whereas liver metastasis was present in 1/5 of the animals treated with gemcitabine alone.

IT 692053-03-5P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-7-(3-chloropropoxy)-6-methoxyquinazoline 692053-08-0P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-6-methoxyquinazoline 692053-18-2P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-23-9P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-29-5P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-6-(2-chloroethoxy)-7-methoxyquinazoline 692053-34-2P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-6-(3-chloropropoxy)-7-methoxyquinazoline 692053-39-7P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-7-(3-chloropropoxy)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-44-4P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-7-[(2,4-dimethoxybenzyl)oxy]-5-isopropoxyquinazoline 692053-55-7P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-59-1P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]quinazoline 692053-88-6P, 7-(N-tert-Butoxycarbonylpiperidin-4-ylmethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-6-methoxyquinazoline 692053-94-4P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-6-methoxy-7-[(piperidin-4-yl)methoxy]quinazoline 692055-28-0P, 5-Isopropoxy-7-[2-(piperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]quinazoline


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(antitumor agent; preparation of quinazoline-containing Src inhibitors for

use

in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)


RN 692053-03-5 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-08-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-18-2 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)






RN 692053-23-9 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-29-5 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(2-chloroethoxy)-7-methoxy- (9CI) (CA INDEX NAME)




RN 692053-34-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(3-chloropropoxy)-7-methoxy- (9CI) (CA INDEX NAME)




RN 692053-39-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692053-44-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-55-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-59-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)- (9CI) (CA INDEX NAME)




RN 692053-88-6 ZCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 692053-94-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 692055-28-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



IT 692053-13-7P, 4-[(5-Chloro-2,3-methylenedioxyppyridin-4-yl)amino]-6-methoxy-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]quinazoline 692053-49-9P, 4-[(5-Chloro-2,3-methylenedioxyppyridin-4-yl)amino]-7-hydroxy-5-isopropoxyquinazoline 692053-63-7P, 7-(2-Chloroethoxy)-4-[(2,3-methylenedioxyppyridin-4-yl)amino]-6-methoxyquinazoline 692053-68-2P, 7-(3-Chloropropoxy)-4-[(2,3-methylenedioxyppyridin-4-yl)amino]-6-methoxyquinazoline 692053-72-8P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxyppyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-76-2P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxyppyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-82-0P, 4-[(5-Chloro-2,3-methylenedioxyppyridin-4-yl)amino]-7-[2-[4-(2-dimethylaminoacetyl)piperazin-1-yl]ethoxy]-5-isopropoxyquinazoline 692054-00-5P, 4-[(5-Chloro-2,3-methylenedioxyppyridin-4-yl)amino]-7-[1-(2-dimethylaminoacetyl)piperidin-4-yl]methoxy]-6-methoxyquinazoline 692054-06-1P, 5-Isopropoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-11-8P, 6-Methoxy-7-[3-[4-isobutylpiperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-16-3P, 6-Methoxy-7-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-22-1P, 6-Methoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-28-7P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-33-4P 692054-44-7P 692054-49-2P, 6-[2-(Morpholino)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-55-0P, 6-[2-(4-Methylpiperazin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-60-7P, 6-[2-(Pyrrolidin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-66-3P, 6-[2-(4-Acetylpiperazin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-72-1P 692054-77-6P, 6-[3-(Pyrrolidin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-83-4P, 6-[3-(Morpholino)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-88-9P, 6-[3-(4-Acetylpiperazin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-94-7P, 6-[3-(4-Methylpiperazin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-00-8P 692055-04-2P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-10-0P, 5-[(Tetrahydropyran-4-yl)oxy]-

7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-16-6P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-22-4P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-34-8P, 5-Isopropoxy-7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-41-7P, 5-Isopropoxy-7-[2-(pyrrolidin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-46-2P, 5-Isopropoxy-7-[2-(piperidino)ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-53-1P, 5-Isopropoxy-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-59-7P, 5-Isopropoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-66-6P 692055-76-8P, 5-Isopropoxy-7-[2-[4-methylpiperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-83-7P, 5-Isopropoxy-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-88-2P, 7-[3-(Morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692055-94-0P, 7-[3-[4-Acetyl-piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692056-00-1P, 6-Methoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 692056-04-5P, 6-Methoxy-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(2,3-methylenedioxy-pyridin-4-yl)amino]quinazoline 694439-00-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antitumor agent; preparation of quinazoline-containing Src inhibitors for

use

in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)


RN 692053-13-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 692053-49-9 ZCAPLUS

CN 7-Quinazolinolamine, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-63-7 ZCAPLUS

CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-68-2 ZCAPLUS

CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-72-8 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692053-76-2 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692053-82-0 ZCAPLUS

CN Piperazine, 1-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-4-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)




RN 692054-00-5 ZCAPLUS

CN Piperidine, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)




RN 692054-06-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-11-8 ZCAPLUS


CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 692054-16-3 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)






RN 692054-22-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 692054-44-7 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692054-49-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692054-55-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692054-60-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-66-3 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-72-1 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692054-77-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692054-83-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692054-88-9 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 692054-94-7 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692055-00-8 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692055-04-2 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-10-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-16-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-22-4 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-34-8 ZCAPLUS  
 CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692055-41-7 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-46-2 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-53-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-59-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-66-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(3R,4S)-3,4-dimethoxy-1-pyrrolidinyl]ethoxy]-5-(1-methylethoxy)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 692055-76-8 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-83-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692055-88-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692055-94-0 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692056-00-1 ZCAPLUS


CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692056-04-5 ZCAPLUS

CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)


10/ 533,931



RN 694439-00-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(4aR,7aS)-hexahydro-6H-1,4-dioxino[2,3-c]pyrrol-6-yl]ethoxy]-5-(1-methylethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692060-97-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

in (intermediate; preparation of quinazoline-containing Src inhibitors for use synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)


RN 692060-97-2 ZCAPLUS

CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 692053-49-9

CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 692060-84-7, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy)pyridin-4-yl]amino]quinazoline 694439-05-9, 7-(2-Chloroethoxy)-4-[(2,3-methylenedioxy)pyridin-4-yl]amino]quinazoline 694439-06-0, 7-(3-Chloropropoxy)-4-[(2,3-methylenedioxy)pyridin-4-yl]amino]quinazoline

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazoline-containing Src inhibitors for use in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)


RN 692060-84-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)- (9CI) (CA INDEX NAME)




RN 694439-05-9 ZCAPLUS

CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl- (9CI) (CA INDEX NAME)



RN 694439-06-0 ZCAPLUS

CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-  
(9CI) (CA INDEX NAME)REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:414727 ZCAPLUS

DOCUMENT NUMBER: 140:423698

TITLE: Preparation of quinazoline derivatives as c-Src  
tyrosine kinase inhibitors

INVENTOR(S): Ple, Patrick

PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.; AstraZeneca Uk Limited

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041829	A1	20040521	WO 2003-GB4703	20031029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2503371	A1 20040521	CA 2003-2503371 20031029
AU 2003278383	A1 20040607	AU 2003-278383 20031029
AU 2003278383	B2 20070614	
EP 1562955	A1 20050817	EP 2003-769689 20031029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
BR 2003015756	A 20050906	BR 2003-15756 20031029
CN 1735617	A 20060215	CN 2003-80108194 20031029
JP 2006506463	T 20060223	JP 2005-502127 20031029
IN 2005DN01534	A 20061229	IN 2005-DN1534 20050415
NO 2005001900	A 20050601	NO 2005-1900 20050419
ZA 2005003337	A 20060726	ZA 2005-3337 20050425
MX 2005PA04858	A 20050722	MX 2005-PA4858 20050504
US 2006122199	A1 20060608	US 2005-533931 20050504
PRIORITY APPLN. INFO.:		EP 2002-292736 A 20021104
		EP 2003-290900 A 20030410
		WO 2003-GB4703 W 20031029
OTHER SOURCE(S):	MARPAT 140:423698	
GI		

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The title compds. I [R1 = halo, CF3, cyano, isocyano, NO3, OH, SH, amino, formyl, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; Z = O, SO, SO2, N(R2)2, or C(R2)2; R2 = H or alkyl; m = 0-3; R3 = halo, CF3, CN, NO2, OH, amino, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; n = 0-3] were prepared as c-Src tyrosine kinase inhibitors in the containment and/or treatment of solid tumor disease. For example, reaction of 4-amino-5-chloro-2,3-methylenedioxypyridine (preparation given) and 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation given) yielded compound II.

IT 692053-03-5P 692053-18-2P 692053-23-9P  
692053-29-5P 692053-34-2P 692053-39-7P  
692053-44-4P 692053-49-9P 692053-55-7P  
692053-59-1P 692053-63-7P 692053-68-2P  
692053-94-4P 692055-28-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)

RN 692053-03-5 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-18-2 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(3-chloropropoxy)]- (9CI) (CA INDEX NAME)



RN 692053-23-9 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-29-5 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(2-chloroethoxy)-7-methoxy- (9CI) (CA INDEX NAME)




RN 692053-34-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(3-chloropropoxy)-7-methoxy- (9CI) (CA INDEX NAME)



RN 692053-39-7 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-44-4 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)






RN 692053-49-9 ZCAPLUS

CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-55-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-59-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 692053-63-7 ZCAPLUS

CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-68-2 ZCAPLUS

CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-94-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 692055-28-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




IT 692053-08-0P 692053-13-7P 692053-72-8P  
 692053-76-2P 692053-82-0P 692053-88-6P  
 692054-00-5P 692054-06-1P 692054-11-8P  
 692054-16-3P 692054-22-1P 692054-28-7P  
 692054-33-4P 692054-44-7P 692054-49-2P  
 692054-55-0P 692054-60-7P 692054-66-3P  
 692054-72-1P 692054-77-6P 692054-83-4P  
 692054-88-9P 692054-94-7P 692055-00-8P  
 692055-04-2P 692055-10-0P 692055-16-6P  
 692055-22-4P 692055-34-8P 692055-41-7P  
 692055-46-2P 692055-53-1P 692055-59-7P  
 692055-66-6P 692055-76-8P 692055-83-7P  
 692055-88-2P 692055-94-0P 692056-00-1P  
 692056-04-5P 693272-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)


RN 692053-08-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 692053-13-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 692053-72-8 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692053-76-2 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692053-82-0 ZCAPLUS

CN Piperazine, 1-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-4-[(dimethylamino)acetyl]- (9CI)  
(CA INDEX NAME)




RN 692053-88-6 ZCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 692054-00-5 ZCAPLUS

CN Piperidine, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)




RN 692054-06-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 692054-11-8 ZCAPLUS

CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 692054-16-3 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)




RN 692054-22-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 692054-44-7 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-49-2 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-55-0 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)






RN 692054-60-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-66-3 ZCAPLUS


CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-72-1 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692054-77-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692054-83-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692054-88-9 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692054-94-7 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-00-8 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692055-04-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propenyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-10-0 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-16-6 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-22-4 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 692055-34-8 ZCAPLUS  
 CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692055-41-7 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-46-2 ZCAPLUS  
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-53-1 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-59-7 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-66-6 ZCAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(3R,4S)-3,4-dimethoxy-1-pyrrolidinyl]ethoxy]-5-(1-methylethoxy)-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 692055-76-8 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 692055-83-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692055-88-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 692055-94-0 ZCAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-quinazolin-2-yl]ethoxy]propyl]- (9CI) (CA INDEX NAME)



RN 692056-00-1 ZCAPLUS


CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692056-04-5 ZCAPLUS

CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)






RN 693272-25-2 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-6-[2-[(3aR,6aS)-tetrahydro-2-methyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 692060-84-7 692060-97-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)

RN 692060-84-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)- (9CI) (CA INDEX NAME)



RN 692060-97-2 ZCAPLUS


CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/ 533,931

CM 1

CRN 692053-49-9

CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



=> d his

(FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007)

FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 60 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007

L4 4 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

21.14

193.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.12

-3.12

STN INTERNATIONAL LOGOFF AT 17:27:51 ON 26 JUL 2007